Sichuan Kelun-Biotech Biopharmaceutical (SEHK:06990) H2 2025 Earnings call March 23, 2026 08:00 AM ET Company ParticipantsDing Nanchao - Deputy General Manager and Chief Marketing OfficerGe Junyou - President and CEOJinbo Zhang - Director of the Analytical DepartmentMatthew Culley - Portfolio ManagerWei Chen - Deputy General Manager and VP of Molecule R&DXiangyang Tan - Chief Scientific OfficerXiao Ping Jin - Chief Medical OfficerZe Jian Zhou - CFOConference Call ParticipantsShen Ziyi - Equity Research Anal ...

WeRide (NasdaqGM:WRD) Q4 2025 Earnings call March 23, 2026 08:00 AM ET Company ParticipantsJennifer Li - CFO and Head of InternationalTony Han - Founder, Chairman, and CEONone - Company RepresentativeConference Call ParticipantsFang Xinyu - Associate AnalystJiajie Shen - Equity Research AnalystLeo You - Research AnalystMing-Hsun Lee - Equity Research AnalystTim Hsiao - Equity AnalystOperatorGood morning and good evening, ladies and gentlemen. Thank you for standing by, and welcome to WeRide's Q4 and full ye ...

Ecolab's Acquisition of CoolIT Systems Conference Call Summary Company and Industry Overview - **Company**: Ecolab - **Acquisition Target**: CoolIT Systems - **Acquisition Value**: $4.75 billion - **Expected Closing**: Q3 2026 - **Industry**: Water technology and services, specifically focused on data centers and microelectronics Key Points and Arguments Acquisition Details - Ecolab has entered into a firm agreement to acquire CoolIT Systems for $4.75 billion, expected to close in Q3 2026, pending customary approvals [3][18] - The acquisition is seen as a strategic move to enhance Ecolab's capabilities in the high-tech water business, particularly in cooling technologies for data centers [3][10] Financial Performance Expectations - Ecolab anticipates adjusted EPS for Q1 2026 to be between $1.69 and $1.71, reflecting a year-over-year growth of 13%-14% [4] - For the full year 2026, excluding CoolIT, Ecolab expects 12%-15% adjusted EPS growth [4][68] - The acquisition of CoolIT is projected to lift Ecolab's total organic sales growth by more than one percentage point starting one year after the close [15] Growth Projections - Ecolab aims for an operating income margin of over 20% by 2027, driven by strong growth in high-margin businesses and innovation [6] - The company expects to achieve 5%-7% organic sales growth, supported by the addition of CoolIT [6][24] Market Dynamics - The liquid cooling market is projected to grow at over 30% annually, with an addressable market reaching approximately $50 billion by 2035 [12] - CoolIT is positioned as a leader in direct-to-chip liquid cooling, currently holding a double-digit market share in North America [13][14] Strategic Synergies - Ecolab plans to leverage CoolIT's technology to enhance its existing offerings, particularly through the integration of 3D TRASAR technology for optimized cooling performance [44][45] - The combined capabilities are expected to create a differentiated end-to-end cooling platform, enhancing customer value and operational efficiency [16][22] Recurring Revenue Model - Ecolab maintains a strong recurring revenue model, with expectations that 90% of its revenue will remain recurring post-acquisition [29][31] - The integration of CoolIT is expected to enhance this model by providing additional consumables and services tied to new technologies [30][31] Capacity and Investment - CoolIT currently has the capacity to double its sales, and Ecolab plans to maintain its existing CapEx model while investing in growth [54][56] - The acquisition is expected to be accretive to Ecolab's long-term sales and EPS growth algorithm, with a focus on maintaining a strong investment-grade profile [17][68] Additional Important Insights - Ecolab's growth strategy is heavily influenced by the increasing demand for AI and data center capabilities, with a focus on water management and cooling solutions [10][81] - The acquisition aligns with Ecolab's historical approach to strategic M&A, focusing on high-return businesses that compound value over time [24] - Ecolab's leadership emphasizes the importance of technology and innovation in driving growth and maintaining competitive advantages in the market [40][41] This summary encapsulates the key points discussed during the conference call regarding Ecolab's acquisition of CoolIT Systems, highlighting the strategic importance, financial expectations, and market dynamics surrounding the deal.

Leadership expanded: Sonova - a 6 billion revenue ambition March 23, 2026 Disclaimer This presentation contains forward-looking statements, which offer no guarantee with regard to future performance. These statements are made on the basis of management's views and assumptions regarding future events and business performance at the time the statements are made. They are subject to risks and uncertainties including, but not confined to, future global economic conditions, exchange rates, legal provisions, mark ...

Sichuan Kelun-Biotech Biopharmaceutical (SEHK:06990) H2 2025 Earnings call March 23, 2026 08:00 AM ET Speaker6Thank you for joining Kelun-Biotech earnings call for 2025 annual results. Within next one hour, we are going to present our business and financial performance in 2025, followed by a Q&A session. Management presentation will be conducted in Mandarin with English interpretation. Please switch to English channel if you prefer English language. This conference call will be recorded and provided to Kelu ...

2026 Investor Day MARCH 23, 2026 Keephills, Alberta Forward-looking statements and non-IFRS measures This presentation includes "forward-looking information," within the meaning of applicable Canadian securities laws, and "forward-looking statements," within the meaning of applicable United States securities laws, including the Private Securities Litigation Reform Act of 1995 (collectively referred to herein as "forward-looking statements"). Forward-looking statements are not facts, but only predictions and ...

Apogee Therapeutics Conference Call Summary Company Overview - **Company**: Apogee Therapeutics (NasdaqGM:APGE) - **Focus**: Development of treatments for atopic dermatitis and type two inflammation Industry Context - **Market Size**: Atopic dermatitis is projected to become the largest I&I market, potentially exceeding $50 billion [4][32] - **Current Treatments**: Limited options exist, with even modestly differentiated products achieving blockbuster status [4] Key Points from the Call Clinical Development and Results - **Drug**: Zumilokibart (Zumi) - **Study**: APECS Part A 52-week maintenance results - **Efficacy**: - 75% maintenance of EASI-75 response with 3-month dosing - 85% maintenance of EASI-75 response with 6-month dosing - 86% maintenance of IGA 0/1 response with 3-month dosing - 78% maintenance of IGA 0/1 response with 6-month dosing [5][12] - **Deepening Responses**: Observed across all endpoints tested, contrasting with Dupixent, which plateaued after week 16 [6][15] - **Safety Profile**: Well-tolerated with adverse events consistent with the IL-13 class, including a 20.2% rate of non-infective conjunctivitis [11][25] Market Opportunity - **Unmet Need**: Significant quality-of-life impact for patients with atopic dermatitis, including sleep loss and mood disorders [21][22] - **Dosing Advantage**: Zumi offers a reduced injection burden (2-4 times per year) compared to standard care (26 times per year) [31][32] - **Potential Launch**: Planned for 2029, with expectations of becoming a first-line treatment option [29][32] Future Directions - **Phase III Trials**: On track to initiate in the second half of the year, with part B results expected in Q2 2026 [29][33] - **Expansion Potential**: Zumi's application may extend to asthma and eosinophilic esophagitis, with positive phase I-B asthma data already disclosed [29] Competitive Landscape - **Comparison with Other Treatments**: Zumi's efficacy and safety profile position it favorably against existing treatments like Dupixent and JAK inhibitors [72] - **Market Penetration**: Atopic dermatitis remains underpenetrated, with new entrants quickly achieving blockbuster status [32] Conclusion - **Strategic Vision**: Apogee aims to establish itself as a leader in the I&I market by delivering innovative treatments that address significant unmet needs in atopic dermatitis [32][34]

Summary of Grab's Acquisition of Foodpanda Taiwan Conference Call Company and Industry - **Company**: Grab (NasdaqGS:GRAB) - **Industry**: Food Delivery Services Key Points and Arguments Acquisition Announcement - Grab announced the acquisition of Delivery Hero's Foodpanda delivery business in Taiwan for **$600 million** in an all-cash transaction, marking Grab's entry into its **ninth market** and first outside Southeast Asia [4][19] Strategic Rationale - **Cultural Familiarity**: The CEO emphasized the cultural ties between Taiwan and Southeast Asia, which will facilitate better understanding of local users [5] - **Urban Density**: Taiwan's urban density is **3.6 times** larger than the Southeast Asian average, allowing for more efficient delivery operations [6] - **Spending Power**: Taiwan is the highest income market outside Singapore, with **70%** of users already using food delivery apps by 2025 [6] - **Demographics**: Over **40%** of households in Taiwan are single-person residences, indicating a strong demand for food delivery services [6] Market Potential - Taiwan's economy grew **9%** in 2025, the strongest growth in 15 years, driven by exports and AI demand [8] - The central bank raised its 2026 GDP growth forecast to **7%**, indicating robust economic conditions [9] - Foodpanda Taiwan generated **$1.8 billion** in GMV across 21 cities in 2025, with a user penetration of just **10%**, suggesting significant growth potential [10] Financial Projections - The acquisition is expected to add over **$40 billion** to Grab's existing **$200 billion** addressable market in Southeast Asia, increasing the total to **$240 billion** [11] - The Foodpanda Taiwan business is projected to contribute at least **$60 million** in incremental Adjusted EBITDA by 2028 [21] Integration and Operational Strategy - Grab plans to migrate users and partners from the Foodpanda app to the Grab app by early 2027, with a focus on leveraging AI tools to enhance partner earnings [19][20] - The integration will involve front-loaded costs, but profitability is expected by the end of 2027 [27] Competitive Landscape - Grab aims to improve driver earnings while reducing consumer prices, a strategy that has proven successful in Southeast Asia [17] - The acquisition positions Grab in direct competition with Uber, which holds a **14%** stake in Grab, but the CEO emphasized a commitment to all shareholders [40] Regulatory Considerations - Grab is committed to building strong relationships with Taiwanese regulators, differentiating this acquisition from previous failed attempts by Uber [38] Future Outlook - Grab remains focused on expanding its presence in Southeast Asia while exploring inorganic growth opportunities like the Taiwan acquisition [36] - The company is also addressing rising fuel prices through targeted subsidies and a transition to electric vehicles (EVs) [44][45] Additional Important Information - The acquisition is seen as a disciplined, strategic move consistent with Grab's growth strategy over the past eight years [21] - The company has a proven integration playbook from previous acquisitions, which will be applied to the Taiwan market [21] This summary encapsulates the key points from Grab's conference call regarding the acquisition of Foodpanda Taiwan, highlighting the strategic rationale, market potential, financial projections, and operational strategies.

Summary of Insmed Phase IIIb ENCORE Study Conference Call Company and Industry - **Company**: Insmed - **Industry**: Pharmaceutical, specifically focusing on treatments for MAC (Mycobacterium avium complex) lung infections Core Points and Arguments 1. **Study Success**: The ENCORE trial demonstrated a statistically significant improvement in respiratory symptom scores for patients treated with ARIKAYCE compared to the placebo group, indicating its effectiveness in treating MAC lung infections [4][10] 2. **Culture Conversion**: The study showed that 82.4% of patients in the ARIKAYCE arm achieved culture conversion by month 13, compared to 55.6% in the control arm, with a highly significant difference of approximately 27 percentage points [14][15] 3. **Durability of Treatment**: The results indicated that the benefits of ARIKAYCE persisted even after treatment cessation, with 76.2% of patients maintaining culture conversion at month 15 [16][17] 4. **Regulatory Submissions**: Insmed plans to pursue regulatory submissions with the FDA and PMDA in the second half of the year, aiming to expand the label to include all patients with MAC lung infections, increasing the addressable patient population from around 30,000 to over 200,000 [6][22] 5. **Safety Profile**: The safety profile of ARIKAYCE was consistent with previous studies, with no new safety signals observed. The treatment discontinuation rate was 18.3%, lower than previous studies, indicating improved tolerability [20][21] 6. **Patient-Reported Outcomes**: The study utilized a validated patient-reported outcome tool, which is a first in this disease state, enhancing the credibility of the findings [5][9] 7. **Market Potential**: The expansion of the patient population and the positive results from the study are expected to lead to significant revenue growth, with potential market penetration anticipated in the next 12-24 months [57][76] Other Important Content 1. **Comparison to Standard of Care**: The study aimed to establish a new standard of care by demonstrating that ARIKAYCE, when added to a two-drug regimen, provides significant benefits in both symptoms and culture conversion [25][26] 2. **Long-term Benefits**: While the study did not specifically assess survival benefits, the durable culture conversion suggests potential long-term advantages for patients, including reduced risk of becoming refractory to treatment [29][31] 3. **Dysphonia Rates**: Dysphonia was reported in 50.7% of patients in the ARIKAYCE arm, but measures to mitigate this side effect have been identified, enhancing the overall benefit-risk profile [36][37] 4. **Real-World Applicability**: The trial population is considered representative of real-world treatment practices, which may facilitate the adoption of ARIKAYCE in clinical settings [42][43] 5. **International Market**: Japan is highlighted as a significant market opportunity due to a higher prevalence of MAC infections, with expectations for continued revenue generation from this region [72][73] This summary encapsulates the key findings and implications from the conference call regarding the ENCORE study and the future of ARIKAYCE in treating MAC lung infections.

WeRide (NasdaqGM:WRD) Q4 2025 Earnings call March 23, 2026 08:00 AM ET Speaker4Good morning and good evening, ladies and gentlemen. Thank you for standing by, and welcome to WeRide's Q4 and full year 2025 earnings conference call. Please note that today's event is being recorded. At this time, all participants are in listen-only mode. For today's call, management will use English as the main language. A third-party interpreter will provide simultaneous Chinese interpretation. The company will be hosting a q ...